Compare Stocks

→ 3 Sub-$10 Stocks to Buy for 2024 (From TradingTips) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNCE Concert Pharmaceuticals	$8.37	$8.37	$2.66 ▼ $8.55	$401.26M	0.52	2.97 million shs	N/A
EVFM Evofem Biosciences	$0.01	$0.02	$0.01 ▼ $4.36	$734K	-1.12	797,591 shs	603,016 shs
EVLO Evelo Biosciences	$0.04	$0.05	$0.03 ▼ $13.93	$834K	2.03	43,770 shs	61,379 shs
KALV KalVista Pharmaceuticals	$11.65 -1.9%	$12.85	$7.21 ▼ $16.88	$491.51M	0.88	755,748 shs	298,645 shs
REPH Recro Pharma		$1.73	$1.38 ▼ $3.79	$117.93M	1.08	126,298 shs	141,800 shs

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNCE Concert Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
EVFM Evofem Biosciences	-11.11%	-24.02%	-27.19%	-65.13%	-99.60%
EVLO Evelo Biosciences	-4.46%	-2.33%	-21.52%	-20.95%	-98.63%
KALV KalVista Pharmaceuticals	-1.94%	-2.35%	-2.84%	-6.50%	+47.47%
REPH Recro Pharma	0.00%	0.00%	0.00%	0.00%	0.00%

Uncover this 2024 Hidden Gem (Ad)

Exclusive Report: Uncover a Hidden Investment Gem We’re excited to share a special report on one exceptional, publicly traded company. This company has achieved a remarkable 22+% just this year, outperforming the market and revealing the potential for significant gains.

[Click here to subscribe] and elevate your trading today.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CNCE Concert Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EVFM Evofem Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EVLO Evelo Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	3.8554 of 5 stars	3.5	1.0	0.0	4.6	2.5	2.5	0.6
REPH Recro Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CNCE Concert Pharmaceuticals	N/A	N/A	N/A	N/A
EVFM Evofem Biosciences	2.00	Hold	N/A	N/A
EVLO Evelo Biosciences	2.00	Hold	N/A	N/A
KALV KalVista Pharmaceuticals	3.00	Buy	$26.33	126.04% Upside
REPH Recro Pharma	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest CNCE, EVLO, EVFM, REPH, and KALV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/11/2024	KALV KalVista Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00
2/14/2024	KALV KalVista Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$16.00 ➝ $24.00
2/13/2024	KALV KalVista Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$22.00 ➝ $35.00

(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CNCE Concert Pharmaceuticals	$32.58M	12.32	N/A	N/A	$3.24 per share	2.58
EVFM Evofem Biosciences	$18.22M	0.04	$1.36 per share	0.01	($2.64) per share	-0.01
EVLO Evelo Biosciences	N/A	N/A	N/A	N/A	($0.92) per share	N/A
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	$4.71 per share	N/A
REPH Recro Pharma	$75.36M	0.00	N/A	N/A	$0.90 per share	0.00

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CNCE Concert Pharmaceuticals	-$80.05M	-$3.21	N/A	N/A	N/A	N/A	-109.43%	-76.65%	N/A
EVFM Evofem Biosciences	$52.98M	-$7.62	N/A	∞	N/A	290.81%	-90.20%	331.20%	4/26/2024 (Estimated)
EVLO Evelo Biosciences	-$114.53M	-$13.29	N/A	∞	N/A	N/A	N/A	-189.58%	5/13/2024 (Estimated)
KALV KalVista Pharmaceuticals	-$92.91M	-$3.15	N/A	N/A	N/A	N/A	-86.06%	-72.65%	7/5/2024 (Estimated)
REPH Recro Pharma	-$11.37M	-$0.31	N/A	N/A	N/A	-15.15%	-56.66%	-11.14%	N/A

Latest CNCE, EVLO, EVFM, REPH, and KALV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/27/2024	Q4 2023	EVFM Evofem Biosciences	N/A	-$0.44	-$0.44	-$0.44	N/A	$4.84 million
3/11/2024	Q3 2024	KALV KalVista Pharmaceuticals	-$0.75	-$0.84	-$0.09	-$0.84	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CNCE Concert Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
EVFM Evofem Biosciences	N/A	N/A	N/A	N/A	N/A
EVLO Evelo Biosciences	N/A	N/A	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
REPH Recro Pharma	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CNCE Concert Pharmaceuticals	N/A	9.03	9.03
EVFM Evofem Biosciences	N/A	0.13	0.10
EVLO Evelo Biosciences	N/A	0.48	0.48
KALV KalVista Pharmaceuticals	N/A	5.44	5.44
REPH Recro Pharma	2.27	3.24	2.74

Ownership

Institutional Ownership

Company	Institutional Ownership
CNCE Concert Pharmaceuticals	70.63%
EVFM Evofem Biosciences	0.22%
EVLO Evelo Biosciences	0.31%
KALV KalVista Pharmaceuticals	N/A
REPH Recro Pharma	62.34%

Insider Ownership

Company	Insider Ownership
CNCE Concert Pharmaceuticals	11.33%
EVFM Evofem Biosciences	0.21%
EVLO Evelo Biosciences	1.02%
KALV KalVista Pharmaceuticals	12.30%
REPH Recro Pharma	14.20%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CNCE Concert Pharmaceuticals	64	47.94 million	42.51 million	Optionable
EVFM Evofem Biosciences	35	53.96 million	53.85 million	Not Optionable
EVLO Evelo Biosciences	66	18.98 million	18.79 million	No Data
KALV KalVista Pharmaceuticals	118	42.19 million	37.00 million	Optionable
REPH Recro Pharma	185	56.42 million	48.41 million	Optionable

CNCE, EVLO, EVFM, REPH, and KALV Headlines

Source	Headline
	Dorf Ketal's Indian unit acquires veterinary pharma brand vccircle.com - April 10 at 10:57 PM
	Fuji Pharma Co. Ltd. wsj.com - January 30 at 3:34 PM
	Aurobindo Pharma Q2 results: Net profit jumps 85% to Rs 757 crore moneycontrol.com - November 22 at 10:47 PM
	Retaining the human element of AI within pharma and healthcare pharmaphorum.com - November 21 at 10:06 AM
	Here's what Wall Street expects from Recro Pharma's earnings report markets.businessinsider.com - November 7 at 12:00 PM
	US supreme court halts Purdue Pharma deal that shields Sacklers from lawsuits theguardian.com - August 16 at 1:59 AM
	Mankind Pharma share price livemint.com - August 9 at 12:30 PM
	What Wall Street expects from Recro Pharma's earnings markets.businessinsider.com - August 9 at 7:25 AM
	Mankind Pharma Ltd (MNKI) investing.com - August 3 at 9:00 AM
	Eversana and Amazon plan generative AI push in pharma pharmaphorum.com - July 30 at 11:21 PM
	Aurobindo Pharma Ltd. ndtv.com - July 25 at 12:39 AM
	Baudax Bio acquires Maryland biotechnology firm TeraImmune; stock jumps bizjournals.com - June 30 at 12:44 PM
	Pharma reform: Patients can’t afford to wait. Act now. politico.eu - June 13 at 3:41 PM
	Sun Pharma reports "information security incident"; isolates impacted IT assets health.economictimes.indiatimes.com - March 9 at 7:26 AM
	Watch: Woody Harrelson Torches Big Pharma During Hilarious Opening Monologue on SNL ijr.com - March 2 at 12:30 AM
	Aurobindo Pharma shares gain even as Q3 profit sinks; board declares 300% dividend moneycontrol.com - February 17 at 8:43 PM
	Paytm, Adani Enterprises, HUL, Sun Pharma, Lupin, Cummins, GAIL, Macrotech Developers stocks in focus financialexpress.com - December 20 at 8:48 AM
	Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Recro Pharma, Inc. Common Stock – SCTL benzinga.com - June 24 at 9:08 AM
	Societal CDMO Inc reuters.com - April 20 at 9:24 AM
	Recro Pharma, Inc.: Recro Announces Name Change to Societal CDMO to Reflect Corporate Expansion and Transformation finanznachrichten.de - March 22 at 10:51 PM
	Recro Pharma Rebrands to Societal CDMO Inc. contractpharma.com - March 22 at 5:51 PM
	Is Recro Pharma (REPH) a Worthy Investment? finance.yahoo.com - March 22 at 8:32 AM
	Recap: Recro Pharma Q4 Earnings benzinga.com - March 1 at 11:55 PM
	Recro Pharma Progresses Addition of Fill/Finish, Lyophilization Capabilities contractpharma.com - February 23 at 9:51 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Concert Pharmaceuticals

NASDAQ:CNCE

Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.

Evofem Biosciences

NASDAQ:EVFM

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women; and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

Evelo Biosciences

NASDAQ:EVLO

Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

KalVista Pharmaceuticals

NASDAQ:KALV

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.

Recro Pharma

NASDAQ:REPH

Recro Pharma, Inc. is a pharmaceutical company, which engages in the contract development and manufacturing organization (CDMO). The firm offers integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Exton, PA.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial